Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Gyre Therapeutics, Inc. on June 10, 2026. The record date for the meeting was April 16, 2026, with 96,994,001 shares of common stock entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
All proposals presented at the Annual Meeting were approved by the stockholders. The specific voting results were as follows:
- Proposal 1 (Election of Directors): Class II nominees David M. Epstein, Ph.D., and Dan Weng, M.D., were elected to serve until the 2029 Annual Meeting.
- Proposal 2 (Executive Compensation): The non-binding advisory vote on executive compensation was approved with 70,478,374 votes for and 34,907 votes against.
- Proposal 3 (Ratification of Auditor): Grant Thornton Zhitong Certified Public Accountants LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Proposal 4 (Conversion of Series B Preferred Stock): The issuance of common stock upon conversion of Series B Convertible Preferred Stock was approved in accordance with Nasdaq Listing Rule 5635(a).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 27, 2026, for detailed descriptions of the proposals.
- Confirm the impact of the Series B Preferred Stock conversion on the company's capital structure and share count.
- Review the upcoming 2026 Annual Report (Form 10-K) for financial performance data not included in this 8-K.